How Joe Rogan, Rick Perry, and a Text to Trump Sparked the Ibogaine Executive Order

The inside story of how ibogaine traveled from unregulated clinics in Mexico to the president’s desk, driven by a conservative ex-governor, a Navy SEAL, and a podcast host with the president’s number.

On April 18, 2026, Joe Rogan stood in the Oval Office and described sending Donald Trump a message about ibogaine treat m ent for veterans. Trump’s response, according to Rogan: “Sounds great. Do you want FDA approval? Let’s do it.” Rogan called the exchange “literally that quick.”

That moment captures how the ibogaine executive order, and the Schedule I psychedelic derived from the West African iboga plant at its center, arrived at the top of federal drug policy. The path from unregulated clinics in Mexico to a presidential signing ceremony runs through a Navy SEAL, a former Texas governor, and two episodes of the world’s most-listened-to podcast.

How Veterans Became the Political Case for Ibogaine Reform

Rick Perry’s advocacy for ibogaine began with a personal friendship. When Navy SEAL Marcus Luttrell, author of Lone Survivor, told Perry he planned to travel to Mexico with other veterans to try ibogaine treatment for veterans with PTSD, Perry was skeptical. The data he reviewed changed his position. He called the evidence “indisputable” and became an advocate, framing his push around veteran care with explicit strategic intent.

Perry has stated publicly that presenting ibogaine through the lens of veteran suffering makes it “approachable to the conservative legislators” whose votes would determine whether access expanded. That framing, veteran care as political cover for psychedelic policy reform, is one of the defining features of how the April EO became possible.

Perry appeared on The Joe Rogan Experience twice: episode #2251 in January 2025 and episode #2477 on April 1, 2026, both alongside Americans for Ibogaine CEO W. Bryan Hubbard. The second appearance aired 17 days before Trump signed the executive order. The line between those two episodes and the Oval Office ceremony is about as direct as political causation gets.

Key Context

Ibogaine has been used in unregulated clinics in Mexico for decades, particularly among U.S. veterans seeking treatment for PTSD, traumatic brain injury, and opioid use disorder. Federal Schedule I status has blocked domestic clinical research, pushing people across the border for access. The structural parallel to cannabis, Schedule I classification driving patients to state-level and cross-border workarounds, is hard to miss.

What the Stanford Ibogaine Study Actually Found

The primary peer-reviewed evidence cited in support of the executive order is a January 2024 observational study in Nature Medicine. Stanford researchers examined the MISTIC protocol, which combines ibogaine with intravenous magnesium sulfate to reduce cardiovascular risk, in 30 male special operations veterans with traumatic brain injuries.

One month after treatment, participants reported average reductions of 88% in PTSD symptoms, 87% in depression symptoms, and 81% in anxiety symptoms relative to baseline. Average disability ratings improved from 30.2 (mild to moderate) to 5.1 (no disability).

These numbers warrant careful reading. The study enrolled 30 participants, all of whom independently chose to seek treatment. There was no randomization and no placebo group. The study’s own authors stated that controlled clinical trials are needed to validate the findings. A 2023 systematic review documented mixed results from available randomized trials and noted high risk of bias across the evidence base. The Stanford results are promising. They are not proof.

Ibogaine’s Cardiac Risk: What the Evidence Shows

Ibogaine’s most serious liability is cardiac toxicity. The compound blocks hERG potassium channels, which prolongs the QT interval and can trigger life-threatening arrhythmias. A 2023 review identified 58 ibogaine-associated emergencies, including 38 deaths. Two of those deaths occurred in clinical study settings.

Frederick Barrett, director of the Johns Hopkins Center for Psychedelic and Consciousness Research, has noted that ibogaine’s known cardiotoxicity has made it difficult to study in the U.S. The MISTIC protocol uses magnesium sulfate to counteract this risk, but whether that approach remains reliably protective across a broader patient population is an open question. The executive order creates a framework for answering it. It does not answer it.

What the Ibogaine Executive Order Does — and Doesn’t Do

The April 18 executive order does not reschedule ibogaine. It does not legalize any psychedelic for recreational use. Legal scholars at Harvard’s Petrie-Flom Center, quoted in coverage by Psychedelics Today, noted that an executive order can direct agencies to prioritize and coordinate, but cannot erase statutory requirements or compel FDA approval.

Concretely, the order does the following:

Issues National Priority Vouchers to qualifying psychedelics, potentially shortening FDA review timelines
Creates a Right to Try pathway for investigational ibogaine access
Allocates $50 million to ARPA-H for state-federal research partnerships
Directs data-sharing between the FDA and the VA
Instructs the attorney general to initiate rescheduling review after successful Phase 3 trials

FDA Commissioner Makary confirmed that IND clearance has been granted for ibogaine, meaning U.S. human clinical trials may now legally begin for the first time. That clearance is the EO’s most concrete near-term consequence.

From Texas to the White House: The Road to Ibogaine Clinical Trials

Texas became the policy laboratory that made the federal order viable. Under Perry’s leadership, the state approved $50 million for ibogaine clinical trials, the largest public investment in ibogaine research in U.S. history. Texas retains at least 20% of any resulting drug revenue, with a quarter of that allocated to a veterans fund. Since Perry and Hubbard’s first JRE appearance, representatives from 15 states convened at the inaugural Aspen Ibogaine Meeting to build a multi-state framework for ibogaine clinical trials.

The coalition supporting the order spans unusual political terrain. Republican congressman Morgan Luttrell, Marcus’s twin brother, partnered with Republican Dan Crenshaw and Democrat Alexandria Ocasio-Cortez to push a psychedelic therapy veterans research provision in the FY2024 National Defense Authorization Act. RFK Jr. acknowledged at the signing ceremony that veterans had been traveling to Mexico for treatment, drawing a direct parallel to the cross-border cannabis access patterns that preceded federal regulatory movement.

Preclinical research suggests ibogaine may produce its effects partly through upregulation of GDNF and BDNF, neurotrophic factors in brain regions central to addiction and stress circuitry. The compound’s active metabolite noribogaine has a substantially longer half-life than the parent drug, which may explain reports of sustained symptom relief. These are preclinical findings. Translation to human neural mechanisms is not yet established.

The distance between an executive order and an approved treatment remains large. Phase 3 randomized controlled trials have not begun. The cardiac safety question has no definitive answer. An observational study with 30 participants, however promising, does not meet the evidence threshold a drug approval requires. The political machinery moved faster than the science. Whether Phase 3 trials can close that gap, safely, is now the central question.

Frequently Asked Questions

What did Trump’s ibogaine executive order actually do?

The April 18, 2026 executive order directed the FDA to issue National Priority Vouchers to qualifying psychedelics, created a Right to Try pathway for investigational ibogaine access, allocated $50 million to ARPA-H for state-federal research partnerships, directed data-sharing between the FDA and the VA, and instructed the attorney general to initiate rescheduling review after successful Phase 3 trials. It did not reschedule ibogaine or legalize any psychedelic for recreational or medical use.

Is ibogaine legal in the United States after the executive order?

Ibogaine remains a Schedule I controlled substance under federal law. The executive order created pathways for accelerated research and investigational access, but rescheduling requires completed Phase 3 clinical trials and a formal regulatory process. FDA IND clearance now allows U.S. human clinical trials to begin legally for the first time.

What is the MISTIC protocol for ibogaine treatment?

MISTIC stands for Magnesium-Ibogaine: the Stanford Traumatic Injury to the CNS protocol. It combines ibogaine with intravenous magnesium sulfate to reduce cardiac risk by counteracting the compound’s effects on cardiac ion channels. A 2024 Nature Medicine study using MISTIC in 30 veterans with traumatic brain injury reported significant reductions in PTSD, depression, and anxiety symptoms. The study lacked a randomized controlled design, and the authors called for clinical trials to validate the findings.

What are the documented risks of ibogaine treatment?

Ibogaine’s primary documented risk is cardiac toxicity. The compound blocks hERG potassium channels, prolonging the QT interval and creating potential for life-threatening arrhythmias. A 2023 review identified 58 ibogaine-associated emergencies, including 38 deaths. Two of those deaths occurred in clinical study settings. Protocols like MISTIC attempt to mitigate cardiac risk with co-administered magnesium sulfate, but whether this approach is reliably protective at scale remains an open question pending Phase 3 results.

How did veterans become the political vehicle for ibogaine research?

Former Texas Governor Rick Perry has described framing ibogaine around veteran care as a deliberate strategy to make the issue approachable to conservative legislators. His advocacy began after Navy SEAL Marcus Luttrell told Perry he planned to travel to Mexico for ibogaine treatment. Perry reviewed the data and became an advocate, appearing twice on The Joe Rogan Experience with Americans for Ibogaine CEO W. Bryan Hubbard. The veteran framing helped build a bipartisan coalition spanning Perry, Congressman Morgan Luttrell, Dan Crenshaw, and Alexandria Ocasio-Cortez.

Was this useful for you? Yes 1 No 0

Why not?